Biosyngen’s liver cancer therapy receives fast track designation

2024-02-02
Pharmaceutical Technology
临床研究临床申请细胞疗法基因疗法快速通道
Biosyngen’s liver cancer therapy receives fast track designation
Preview
来源: Pharmaceutical Technology
BST02 is being developed to treat liver cancer, including hepatocellular carcinoma and cholangiocarcinoma. Credit: Peakstock / Shutterstock.com.
Biosyngen’s liver cancer therapy receives fast track designation
Preview
来源: Pharmaceutical Technology
The US Food and Drug Administration (FDA) has granted fast track designation (FTD) to Biosyngen’s T cell therapy BST02 for treating liver cancer, including hepatocellular carcinoma and cholangiocarcinoma.
The designation will accelerate the clinical trial process and marketing registration for BST02.
BST02 utilises adoptive immune cell therapy technology, expanding the patient’s own tumour-infiltrating lymphocytes. This approach offers potential benefits over standard tumour-infiltrating lymphocyte (TIL) therapies, including the ability to be cryopreserved and transported and a reduced requirement for high doses of interleukin-2.
In October 2023, the company received FDA approval to commence the Phase I/II clinical trials of the cell therapy.
The China National Drug Administration’s Center for Drug Evaluation granted approval for the trial in December.
See Also:Vivet wins $5.3m grant to develop gene therapy for rare metabolic disorder
Biosyngen’s liver cancer therapy receives fast track designation
Preview
来源: Pharmaceutical Technology
CMS sets up negotiating framework for expensive sickle cell disease gene therapies
Biosyngen’s liver cancer therapy receives fast track designation
Preview
来源: Pharmaceutical Technology
This marks a significant milestone as BST02 becomes the first TIL cell therapy drug for liver cancer to enter clinical stages globally.
The FTD for BST02 follows a similar designation for another Biosyngen product, BRG01, in July 2023.
Biosyngen aims to continue its research efforts to improve patient outcomes worldwide.
Biosyngen co-founder and CEO Michelle Chen expressed her gratitude to the FDA for recognising the company’s fourth product.
She highlighted the company’s commitment to advancing cancer cell therapy across the globe and offering new treatments for a diverse patient population.
Chen reaffirmed the company’s dedication to using its advanced technology platforms to deliver accessible therapies for patients around the world.
In September 2023, the company received FDA IND clearance for a Phase I/II trial of its therapy, BRL03, to treat lung cancer, gastric cancer and other advanced solid tumours.
BRL03 is the first T cell receptor product developed by the company to enter the clinics.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.
By Cytiva Thematic
Biosyngen’s liver cancer therapy receives fast track designation
Preview
来源: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。